These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The role of treprostinil in the management of pulmonary hypertension. Skoro-Sajer N; Lang I Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755 [TBL] [Abstract][Full Text] [Related]
3. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039 [TBL] [Abstract][Full Text] [Related]
6. Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics. Siehr SL; Ivy DD; Miller-Reed K; Ogawa M; Rosenthal DN; Feinstein JA J Heart Lung Transplant; 2013 May; 32(5):546-52. PubMed ID: 23453572 [TBL] [Abstract][Full Text] [Related]
7. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Simonneau G; Barst RJ; Galie N; Naeije R; Rich S; Bourge RC; Keogh A; Oudiz R; Frost A; Blackburn SD; Crow JW; Rubin LJ; Am J Respir Crit Care Med; 2002 Mar; 165(6):800-4. PubMed ID: 11897647 [TBL] [Abstract][Full Text] [Related]
8. Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension. Walkey AJ; Fein D; Horbowicz KJ; Farber HW Pulm Pharmacol Ther; 2011 Aug; 24(4):421-5. PubMed ID: 21251994 [TBL] [Abstract][Full Text] [Related]
9. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Sadushi-Kolici R; Jansa P; Kopec G; Torbicki A; Skoro-Sajer N; Campean IA; Halank M; Simkova I; Karlocai K; Steringer-Mascherbauer R; Samarzija M; Salobir B; Klepetko W; Lindner J; Lang IM Lancet Respir Med; 2019 Mar; 7(3):239-248. PubMed ID: 30477763 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Tapson VF; Gomberg-Maitland M; McLaughlin VV; Benza RL; Widlitz AC; Krichman A; Barst RJ Chest; 2006 Mar; 129(3):683-8. PubMed ID: 16537868 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827 [TBL] [Abstract][Full Text] [Related]
12. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Rubenfire M; McLaughlin VV; Allen RP; Elliott G; Park MH; Wade M; Schilz R Chest; 2007 Sep; 132(3):757-63. PubMed ID: 17400684 [TBL] [Abstract][Full Text] [Related]
13. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension. Chakinala MM; Feldman JP; Rischard F; Mathier M; Broderick M; Leedom N; Laliberte K; White RJ J Heart Lung Transplant; 2017 Feb; 36(2):193-201. PubMed ID: 27469018 [TBL] [Abstract][Full Text] [Related]
14. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension. Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038 [TBL] [Abstract][Full Text] [Related]
15. Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension. Reisbig KA; Coffman PA; Floreani AA; Bultsma CJ; Olsen KM Ann Pharmacother; 2005 Apr; 39(4):739-43. PubMed ID: 15755791 [TBL] [Abstract][Full Text] [Related]
16. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Badesch DB; Tapson VF; McGoon MD; Brundage BH; Rubin LJ; Wigley FM; Rich S; Barst RJ; Barrett PS; Kral KM; Jöbsis MM; Loyd JE; Murali S; Frost A; Girgis R; Bourge RC; Ralph DD; Elliott CG; Hill NS; Langleben D; Schilz RJ; McLaughlin VV; Robbins IM; Groves BM; Shapiro S; Medsger TA Ann Intern Med; 2000 Mar; 132(6):425-34. PubMed ID: 10733441 [TBL] [Abstract][Full Text] [Related]
17. Treprostinil for pulmonary hypertension. Skoro-Sajer N; Lang I; Naeije R Vasc Health Risk Manag; 2008; 4(3):507-13. PubMed ID: 18827901 [TBL] [Abstract][Full Text] [Related]
18. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490 [TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy and Management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension. Levy M; Del Cerro MJ; Nadaud S; Vadlamudi K; Colgazier E; Fineman J; Bonnet D; Adatia I Int J Cardiol; 2018 Aug; 264():153-157. PubMed ID: 29650343 [TBL] [Abstract][Full Text] [Related]
20. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Vachiéry JL; Hill N; Zwicke D; Barst R; Blackburn S; Naeije R Chest; 2002 May; 121(5):1561-5. PubMed ID: 12006444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]